Lurbinectedin is a drug that has been studied for its effectiveness in treating different types of cancers. According to the sources provided, Lurbinectedin has shown promise in treating small cell lung cancer (SCLC) and other types of solid tumors.

A study published in the Journal of Clinical Oncology [2] evaluated the efficacy of Lurbinectedin in patients with SCLC. The study found that Lurbinectedin had a response rate of 35.2% in patients with relapsed SCLC. The study also found that Lurbinectedin was generally well-tolerated by patients.

Another study published in the Journal of Thoracic Oncology [3] evaluated the combination of Lurbinectedin and Pembrolizumab in patients with relapsed SCLC. The study found that the combination was safe and effective, with a response rate of 70% in patients with relapsed SCLC.

In addition to SCLC, Lurbinectedin has also shown promise in treating other types of solid tumors. According to DrugPatentWatch [1], Lurbinectedin is being studied for its effectiveness in treating ovarian cancer, breast cancer, and other types of solid tumors.

In conclusion, Lurbinectedin has shown promise in treating different types of cancers, particularly SCLC and other types of solid tumors. However, more research is needed to fully understand its effectiveness and potential side effects in treating these cancers.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.cancernetwork.com/view/preliminary-results-show-second-line-lurbinectedin-plus-pembrolizumab-safe-effective-in-relapsed-sclc.